August 2022: Kune varwere vakuru vane metastatic isiri-diki cell yemapapu cancer (NSCLC) vane mabundu ane shanduko inokonzeresa mesenchymal-epithelial transition (MET) exon 14 kusvetuka, sezvaonekwa neFDA-yakatenderwa bvunzo, iyo Food and Drug Administration yakapa capmatinib (Tabrecta). , Novartis Pharmaceuticals Corp.) mvumo yenguva dzose.
Zvichienderana neyekutanga chiyero chekupindura uye nguva yekupindura muGEOMETRY mono-1 kuyedzwa (NCT02414139), yakawanda-yakasiyana-siyana, isina-randomized, yakavhurika-label, yakawanda-cohort research, capmatinib yakambopihwa kukurumidza kubvumidzwa kwechiratidzo chimwe chete muna Chivabvu. 6, 2020. Kubva pane data kubva kune vamwe varwere ve63 uye imwezve mwedzi ye22 yekutevera kuti uongorore kusimba kwekupindura uye kusimbisa rubatsiro rwekurapa, kutendeuka kune kubvumirwa nguva dzose kwakaitwa.
Varwere 160 vane NSCLC yepamusoro ine mutation skipping exon 14 yeMET yakaratidza kushanda. Varwere vakagamuchira capmatinib 400 mg kaviri zuva kusvikira chirwere chavo chichifambira mberi kana kuti migumisiro yakave isingagoneki.
Dare Rakapofumadzwa Rakazvimiririra Rokuongorora rakasarudza iyo ORR uye nguva yekupindura (DOR) seyakanyanya kushanda matanho (BIRC). 60 vanhu vakanga vasati vambogamuchira kurapwa vaiva neORR ye68% (95% CI: 55, 80) uye DOR yemwedzi 16.6 (95% CI: 8.4, 22.1). IORR yaiva 44% (95% CI: 34, 54) pakati pevarwere ve100 vakanga vambogamuchira kurapwa, uye DOR yaiva mwedzi 9.7 (95% CI: 5.6, 13).
The patients’ average age was 71 years (48 to 90). The following specific demographics were reported: 61% female, 77% White, 61% never smoked, 83% had adenocarcinoma, and 16% had metastases to the central nervous system. 81% of patients who had previously had treatment had only gotten one line of systemic therapy; 16% had received two; and 3% had received three. 86% of patients who had previously had treatment had platinum-based chemotherapy.
Varwere vakawana edoema, kusvotwa, kurwadziwa kwetsandanyama, kuneta, kurutsa, dyspnea, kukosora, uye kuderera kwechido kazhinji (20%).
Capmatinib inofanira kutorwa nemuromo kaviri zuva nezuva pamuyero we400 mg, pamwe kana pasina kudya.
Wona ruzivo rwakazara rwekuraira kweTabrecta
